Skip to content

CardioMech Raises $13 Million for Transcatheter Mitral Chordal Repair Technology


CardioMech AS (“CardioMech”) announced that the company successfully raised $13 Million in capital in addition to the $18.5 Million Series A financing in 2020 bringing total funding to $42 Million.

CardioMech is a clinical-stage medical technology company based out of Norway that is developing a catheter-based therapy device for treating mitral regurgitation. According to the Mayo Clinic and American Heart Association, mitral regurgitation is the most common type of heart valve disease that occurs when the flaps of the mitral valve do not close properly, causing backward flow of blood back to the heart. CardioMech describes its investigational device as an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. The artificial chord extends between a flap of the mitral valve and a wall of the left ventricle. An image of the investigational device from CardioMech’s website is shown below:

Jacob Bergsland, Founder of CardioMech, stated that:

[t]here is a significant need for a less-invasive technology that can eliminate mitral regurgitation in younger and healthier patients and Norwegian-born CardioMech is developing a category-defining technology that may benefit patient’s suffering from mitral regurgitation around the world.

According to Allied Market Research, the market to treat mitral regurgitation has increased from $2.5 Billion in 2021 and is expected to reach $5.7 Billion by 2031 growing at a CAGR of 8.8% from 2022 to 2031.

The full press release from CardioMech is available here.


, ,

CardioMech Raises $13 Million for Transcatheter Mitral Chordal Repair Technology Headshot

Matthew Whitehead

Matt is an associate in our Seattle office. His practice includes several areas of intellectual property law, including patent drafting, due diligence, infringement analysis, trademark registration, and licensing. Matt has assisted clients with a diverse range of technologies, such as:

Medical technology: including cancer therapies, orthotic boots and slings, and advanced medical devices for surgery and imaging

Robotic technology: encompassing waste sorting and parcel processing robots, wearable exoskeleton devices, and cutting-edge micro-surgery robots

Space technology: featuring biowaste recycling systems, launch vehicle landing systems, and innovative propulsion systems

Food processing technology: including in automated systems for sorting food items and deboning animal products

Artificial flooring technology: encompassing state-of-the-art products and manufacturing methods for laminate flooring

Prior to joining the firm, Matt worked for Kinex Medical Company as a product engineer and a director of manufacturing operations. In these roles, he played a crucial part in designing and supervising the production of a tablet-powered knee Continuous Passive Motion (CPM) device. Matt also gained valuable legal experience as a law clerk for the Utah Attorney General’s Office in the Tax and Antitrust Division, where he contributed to antitrust regulation efforts in Utah.

Matt earned his Juris Doctor from the University of Utah - S.J. Quinney College of Law. While there, he served on the executive board of the Student Intellectual Property Law Association and was a Note and Comment Editor for the Utah Law Review. Matt also holds a bachelor's degree in mechanical engineering, with an emphasis in robotics and controls, from the University of Utah.

View all posts published by Matthew Whitehead
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal